ArticleDeveloping world bioethics2013
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
Article in Developing world bioethics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Trial
- Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.The lancet. HIV · 2021Trial
- Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.Journal of the International AIDS Society · 2020Trial
- Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017).Journal of acquired immune deficiency syndromes (1999) · 2019Trial
- Article
- Counterfactual Groups to Assess Vaccine or Treatment Efficacy in HIV Prevention Trials in High-Risk Populations in Uganda.Vaccines · 2025Article
- Review
- Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.Journal of virus eradication · 2024Article
- Standard of prevention for infectious diseases' prevention clinical trials during pandemics: learning lessons for global policies from biomedical HIV prevention clinical trials and a case study of COVID-19.Frontiers in public health · 2024Article
- A partner protection package for HIV cure-related trials involving analytical treatment interruptions.The Lancet. Infectious diseases · 2023Review
- Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.BMC medical ethics · 2021Article
- Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial.Clinical trials (London, England) · 2021Review
- Shifts in UNAIDS ethics guidance and implications for ethics review of preventive HIV vaccine trials.Journal of the International AIDS Society · 2021Review
- Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.HIV research & clinical practice · 2021Article
- HIV prevention research and COVID-19: putting ethics guidance to the test.BMC medical ethics · 2021Article
- Article
- A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.Journal of virus eradication · 2020Article
- Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials.The lancet. HIV · 2019Review
- Addressing ethical challenges in HIV prevention research with people who inject drugs.Journal of medical ethics · 2018Article
- Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM.Journal of acquired immune deficiency syndromes (1999) · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks--either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV--expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the feasibility of future HIV prevention trial designs have intensified. This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.